Targeting eNOS for stroke protection

Trends in Neurosciences

Volumn 27, Issue 5, 2004, Pages 283-289

  Endres, Matthias ^a   Laufs, Ulrich ^b   Liao, James K ^c   Moskowitz, Michael A ^d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ARGININE; BRADYKININ; CALCIUM; CALMODULIN; CAVEOLIN 1; CAVEOLIN 3; CHOLESTEROL; CITRULLINE; CONJUGATED ESTROGEN; CORTICOSTEROID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVANOID; GESTAGEN; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; POLYPHENOL; PROTEIN KINASE B; SIMVASTATIN;

ARTERY DILATATION; BIOAVAILABILITY; BLOOD VESSEL FUNCTION; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CELL MEMBRANE; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIETARY INTAKE; DOSE RESPONSE; DRUG TARGETING; GOOD CLINICAL PRACTICE; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LACTIC ACIDOSIS; LEUKOCYTE ADHERENCE; LONG TERM CARE; NEOVASCULARIZATION (PATHOLOGY); NEUROPROTECTION; NONHUMAN; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REBOUND; REPERFUSION INJURY; REVIEW; RISK FACTOR; SHEAR STRESS; STROKE; THROMBOCYTE AGGREGATION; UPREGULATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; GONADAL STEROID HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOTOR ACTIVITY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NUTRITION PHYSIOLOGY; UP-REGULATION;

EID: 1942500993     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2004.03.009     Document Type: Review

References (68)

1. Dirnagl U., et al. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:1999;391-397.
2. Gladstone D.J., et al. Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 33:2002;2123-2136.
3. Loscalzo J. Nitric oxide and vascular disease. N. Engl. J. Med. 333:1995;251-253.
4. Rudic R.D., Seesa W.C. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am. J. Hum. Genet. 64:1999;673-677.
5. Iadecola C. Bright and dark sides of nitric oxide in ischaemic brain injury. Trends Neurosci. 20:1997;132-139.
6. Samdani A.F., et al. Nitric oxide synthase in models of focal ischemia. Stroke. 28:1997;1283-1288.
7. Furchgott R.F., Zawadszki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
8. Huang P.L., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377:1995;239-242.
9. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:2003;R1-R12.
10. Fulton D., et al. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J. Pharmacol. Exp. Ther. 299:2001;818-824.
11. Laufs U., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106:2000;15-24.
12. Dimmeler S., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
13. Fulton D., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:1999;597-601.
14. Huang Z., et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. 16:1996;981-987.
15. Dalkara T., et al. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am. J. Physiol. 267:1994;H678-H683.
16. Murohara T., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101:1998;2567-2578.
17. Aichner A., et al. Essential role of endothelial nitric oxide synthase for the mobilization of stem and progenitor cells. Nat. Med. 9:2003;1370-1376.
18. Dimmeler S., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J. Clin. Invest. 108:2001;391-397.
19. Laufs U., et al. Physical training increases endothelial progenitor cells, inhibits neointima formation and enhances angiogenesis. Circulation. 109:2004;220-226.
20. Zhang Z.G., et al. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ. Res. 90:2002;284-288.
21. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58:2003;719-731.
22. Hernandez-Perera O., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101:1998;2711-2719.
23. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271.
24. Laufs U., et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 102:2000;3104-3110.
25. Kureishi Y., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6:2000;1004-1010.
26. Endres M., et al. Stroke protection by HMG-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8880-8885.
27. Yamada M., et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow Metab. 20:2000;709-717.
28. Sironi L., et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 23:2003;322-327.
29. Kawashima S., et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 34:2003;157-163.
30. Heart Protection Study Collaborative Group (2002) MR/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomized placebo-controlled trial. Lancet 360, 7-22.
31. Jonsson N., Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-reference study. Stroke. 32:2001;1112-1115.
32. O' Driscoll G., et al. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
33. Waters D.D., et al. Reducing the risk for stroke in patients with myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation. 106:2002;1690-1695.
34. Thomas M., Mann J. Increased thrombotic vascular events after change of statin. Lancet. 102:2000;3104-3110.
35. Heeschen C., et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 105:2002;1446-1452.
36. Gertz K., et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 34:2003;551-557.
37. Vecchione C., Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91:2002;173-179.
38. Hafezi-Maghadam A., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8:2002;473-479.
39. Limbourg F.P., et al. Rapid nontranscriptional activation of endothelial nitric oxides synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Invest. 110:2002;1729-1738.
40. Stead L.G., Rowe B.H. Corticosteroid treatment for acute ischaemic stroke. Ann. Emerg. Med. 42:2003;150-152.
41. Chambliss K.L., Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23:2002;665-686.
42. Simoncini T., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 407:2000;538-541.
43. Simoncini T., et al. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 105:2002;1368-1373.
44. Hurn P.D., Brass L.M. Estrogen and stroke. A balanced analysis. Stroke. 34:2003;338-344.
45. Prorock A.J., et al. Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 284:2003;H133-H144.
46. Wassertheil-Smoller S., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the women's health initiative: a randomised trial. J.A.M.A. 289:2003;2673-2684.
47. Fukai T., et al. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J. Clin. Invest. 105:2000;1631-1639.
48. Kojda G., et al. Dysfunctional regulation of endothelial nitric oxide synthase (eNOS) expression in response to exercise in mice lacking one eNOS gene. Circulation. 103:2001;2839-2844.
49. Endres M., et al. Mechanisms of stroke protection by physical activity. Ann. Neurol. 54:2003;582-590.
50. Hambrecht R., et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 107:2003;3152-3158.
51. Wallerath T., et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 106:2002;1652-1658.
52. Benito S., et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br. J. Pharmacol. 135:2002;910-916.
53. Huang S.S., et al. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 69:2001;1057-1065.
54. Vasquez-Vivar J., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of co-factors. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9220-9225.
55. Kuzkaya N., et al. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols. J. Biol. Chem. 278:2003;22546-22554.
56. Landmesser U., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111:2003;1201-1209.
57. Wassmann S., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor and Rac GTPase. Mol. Pharmacol. 59:2001;646-654.
58. Wang X.L., Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol. Genet. Metab. 70:2000;241-251.
59. Hassan A., Markus H.S. Genetics and ischaemic stroke. Brain. 123:2000;1784-1812.
60. Nasreen S., et al. T-786C polymorphism in endothelial NO synthase gene affects cerebral circulation in smokers. Possible gene-environmental interaction. Arterioscler. Thromb. Vasc. Biol. 22:2002;605-610.
61. Nakayama M., et al. T-786-C mutation in the 5′ flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 99:1999;2864-2870.
62. Tesauro M., et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2832-2835.
63. Elbaz A., et al. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. Stroke. 31:2000;1634-1639.
64. Lembo G., et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke. 32:2001;735-740.
65. Mac Leod, M.J. et al. (1999) No association between Glu/Asp polymorphisms of NOS 3 gene and ischaemic stroke. Neurology 53, 418-420.
66. Markus H., et al. Endothelial nitric oxide synthase exon 7 polymorphism, ischaemic cerebrovascular disease, and carotid atheroma. Stroke. 29:1998;1908-1911.
67. Lee C.D., et al. Physical activity and stroke risk. A meta-analysis. Stroke. 34:2003;2475-2482.
68. Di Castelnuovo, A. et al. (2002) Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105, 2836-2844.